Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).


Journal Article

15082 Background: As mCRC survival increases beyond 2 years, patients (pts) have more exposure to multiple CT regimens. Insight into patterns of care in mCRC treatment is crucial to understanding physician and patient decision-making priorities. METHODS: Using a population-based strategy, we identified CRC cases from 1 academic and 9 community oncology practices in the southeastern US with mCRC diagnosed between 6/03-6/06, and treatment with an oxaliplatin- (O) or irinotecan- (IR) based CT regimen during that period. Demographic, disease, treatment, and toxicity data were abstracted by retrospective chart review, double-entered and verified for accuracy. RESULTS: Of 743 charts screened, 110 were eligible: mean age 57.9 (SD 12.2), 74% Stage IV at diagnosis, 39% male, 53% white, 26% black, and 13% ≥70 years. As part of 1st-line mCRC CT, 100% of pts received regimens containing 5-fluorouracil (5-FU), 87% (95% CI 81-93%) received O, 12% (95% CI 6-18%) received IR, and 74% (95% CI 66-82%) received bevacizumab (B). The proportions of pts receiving subsequent lines of CT were: 2nd-line 48% (n=53), 3rd-line 26% (n=29), 4th-line 14% (n=15), and 5th-line 5% (n=5). From 1st to 3rd line, the use of O and B decreased, while IR use increased (see Table ). Therapy was discontinued 29% of the time for disease progression (PD) and 19% of the time for toxicity; 27% had no reason documented. 22% (n=25/114) of O- and 34% (n=20/59) of IR-containing regimens were discontinued for PD. 19% (n=21/114) of O- and 20% (n=12/59) of IR-containing regimens were discontinued for toxicity. CONCLUSIONS: Along with 5-FU, O and B were most commonly used in 1st-line for mCRC. Use of O decreased and IR increased as treatment progressed beyond 1st-line. [Table: see text] [Table: see text].

Full Text

Duke Authors

Cited Authors

  • Herndon, JE; Zafar, Y; Marcello, J; Wheeler, J; Rowe, K; Morse, MA; Abernethy, AP

Published Date

  • May 20, 2008

Published In

Volume / Issue

  • 26 / 15_suppl

Start / End Page

  • 15082 -

PubMed ID

  • 27950330

Electronic International Standard Serial Number (EISSN)

  • 1527-7755


  • eng

Conference Location

  • United States